Literature DB >> 19577170

Diffuse large B-cell lymphomas and burkitt lymphoma.

Laurence de Leval1, Robert Paul Hasserjian.   

Abstract

Diffuse large B-cell lymphomas (DLBCLs) and Burkitt lymphoma (BL) account for the majority of aggressive lymphomas in adults and children. DLBCLs exhibit marked biological heterogeneity and variable clinical presentation and clinical course. Conversely, BL is genetically relatively homogeneous but associated with variable clinicopathological features. In this article, the authors summarize the recent advances pertaining to these B-cell neoplasms, following the latest World Health Organization classification and focusing on changes introduced since the previous edition. These changes include the addition of variants and subgroups of DLBCLs and "borderline" categories for high-grade B-cell neoplasms that show features intermediate between DLBCL and classical Hodgkin lymphoma, or between DLBCL and BL. In particular, the diagnostic and therapeutic problems related to neoplasms with features intermediate between DLBCL and BL will be discussed.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19577170     DOI: 10.1016/j.hoc.2009.04.004

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  15 in total

1.  Rap GTPase-mediated adhesion and migration: A target for limiting the dissemination of B-cell lymphomas?

Authors:  Kevin B L Lin; Spencer A Freeman; Michael R Gold
Journal:  Cell Adh Migr       Date:  2010-07-04       Impact factor: 3.405

2.  B cell lymphoma unclassifiable with features intermediate between diffuse large B cell and burkitt lymphoma--presented with multiple lymphomatous polyposis of gastrointestinal tract.

Authors:  Deepali Jain; Shyam Agrawal; Prem Chopra
Journal:  J Gastrointest Cancer       Date:  2011-12

3.  Immune Evasion by B-cell Lymphoma.

Authors:  Jason M God; Azizul Haque
Journal:  J Clin Cell Immunol       Date:  2011-11-16

4.  Burkitt lymphoma: pathogenesis and immune evasion.

Authors:  Jason M God; Azizul Haque
Journal:  J Oncol       Date:  2010-10-05       Impact factor: 4.375

5.  The next step for Burkitt lymphoma.

Authors:  Bin Cho
Journal:  Korean J Hematol       Date:  2011-06-21

6.  Factors influencing time to diagnosis and initiation of treatment of endemic Burkitt Lymphoma among children in Uganda and western Kenya: a cross-sectional survey.

Authors:  Geoffrey C Buckle; Jennifer Pfau Collins; Peter Odada Sumba; Beccy Nakalema; Dorine Omenah; Kristine Stiffler; Corey Casper; Juliana A Otieno; Jackson Orem; Ann M Moormann
Journal:  Infect Agent Cancer       Date:  2013-09-30       Impact factor: 2.965

7.  The collagen prolyl hydroxylases are novel transcriptionally silenced genes in lymphoma.

Authors:  E Hatzimichael; C Lo Nigro; L Lattanzio; N Syed; R Shah; A Dasoula; K Janczar; D Vivenza; M Monteverde; M Merlano; A Papoudou-Bai; M Bai; P Schmid; J Stebbing; M Bower; M J S Dyer; L E Karran; C ElguetaKarstegl; P J Farrell; A Thompson; E Briasoulis; T Crook
Journal:  Br J Cancer       Date:  2012-09-06       Impact factor: 7.640

Review 8.  Management of relapsed-refractory diffuse large B cell lymphoma.

Authors:  Lalit S Raut; Prantar P Chakrabarti
Journal:  South Asian J Cancer       Date:  2014-01

Review 9.  Biomarkers of HIV-associated Cancer.

Authors:  Brian Thabile Flepisi; Patrick Bouic; Gerhard Sissolak; Bernd Rosenkranz
Journal:  Biomark Cancer       Date:  2014-07-03

Review 10.  Burkitt's lymphoma masquerading as appendicitis--two case reports and review of the literature.

Authors:  Elroy P Weledji; Marcelin N Ngowe; John S Abba
Journal:  World J Surg Oncol       Date:  2014-06-18       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.